Page last updated: 2024-08-25

buparvaquone and Leishmaniasis, Cutaneous

buparvaquone has been researched along with Leishmaniasis, Cutaneous in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Croft, SL; Garnier, T; Järvinen, T; Koskinen, A; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J	1
Adewusi, O; Adriana de Jesus, J; Auxiliadora Dea-Ayuela, M; Bolas-Fernandez, F; Dalastra Laurenti, M; Felipe Domingues Passero, L; Lalatsa, A; Serrano, DR; Statts, L	1
Awan, MM; Jamal, Q; Khan, NH; Shah, A; Sutherland, C; Wahid, S	1
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA	1
Brown, MB; Croft, SL; Garnier, T; Järvinen, T; Lawrence, MJ; Mäntylä, A	1
Brown, M; Croft, S; Garnier, T; Järvinen, T; Lawrence, J; Mäntylä, A	1

Reviews

1 review(s) available for buparvaquone and Leishmaniasis, Cutaneous

Article	Year
Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert opinion on drug delivery, 2012, Volume: 9, Issue:9 Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption	2012

Other Studies

5 other study(ies) available for buparvaquone and Leishmaniasis, Cutaneous

Article	Year
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1 Topics: Administration, Oral; Administration, Topical; Alkaline Phosphatase; Animals; Antiprotozoal Agents; Cricetinae; Female; Humans; Hydrolysis; In Vitro Techniques; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Naphthoquinones; Organophosphates; Permeability; Prodrugs; Skin; Solubility; Water	2004
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis. International journal of pharmaceutics, 2020, Oct-15, Volume: 588 Topics: Animals; Antiprotozoal Agents; Hydrogels; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Naphthoquinones	2020
In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs. Experimental parasitology, 2015, Volume: 154 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line, Tumor; Child; Humans; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages; Male; Meglumine; Meglumine Antimoniate; Naphthoquinones; Organometallic Compounds; Pakistan; Parasitic Sensitivity Tests	2015
Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:1 Topics: Administration, Cutaneous; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Ethanol; Female; Humans; In Vitro Techniques; Leishmaniasis, Cutaneous; Melanins; Mice; Mice, Inbred BALB C; Myristates; Naphthoquinones; Organophosphates; Polyethylene Glycols; Prodrugs; Propylene Glycol; Skin; Skin Absorption	2007
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4 Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Female; Leishmania donovani; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Naphthoquinones; Prodrugs; Skin	2007